RecallRadar

FDA Drug recall D-0045-2025

Hydralazine HCl Tablets, USP, 25mg, Rx only, 100 tablets per carton, Distributed by: Avet Pharmaceuticals Inc., East Brunswick, NJ 08816, D…

On 2024-11-20 the FDA classified a Class III recall of Hydralazine HCl Tablets, USP, 25mg, Rx only, 100 tablets per carton, Distributed by: Avet Pharmaceuticals Inc., East Brunswick, NJ 08816, D… by The Harvard Drug Group, citing failed Impurities/Degradation Specifications; during routine stability testing for impurities.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0045-2025
ClassificationClass III
Statusterminated
Initiated2024-11-05
Published2024-11-20
Last updated2026-09-13 11:52 UTC
CompanyThe Harvard Drug Group
DistributionUS

Product

Hydralazine HCl Tablets, USP, 25mg, Rx only, 100 tablets per carton, Distributed by: Avet Pharmaceuticals Inc., East Brunswick, NJ 08816, Distributed by: MAJOR Pharmaceuticals, Livonia, MI, 48152, USA, NDC 0904-6441-61.

Reason

Failed Impurities/Degradation Specifications; during routine stability testing for impurities.

Identifiers

code_infoLot#: T04888, Exp 11/2024; T04946, Exp 12/2024; T04970, Exp 07/2025

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0045-2025%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.